Jeremy Capes
Partner, International Tax Advisory – Transfer Pricing
KPMG Australia
Jeremy has over 19 years’ experience in transfer pricing advisory, global structural planning and transfer pricing dispute resolution. He has led the Australian Pharmaceutical and Life Sciences focus in Transfer Pricing for a number of years.
Jeremy previously worked in New York specialising in the pharmaceutical and biotechnology sectors covering a broad range of issues including the valuation and migration of intellectual property, managing the costs and risks of pipeline development and collaborative research, economic quantification of risk, identifying and valuing high value services and defining economic substance, and the preparation of global masterfile documentation.
Throughout his career, Jeremy has specialised in value chain analysis and business transformation issues, undertaken numerous supply chain optimisation projects and has significant experience in managing business transformation projects from concept through to implementation.
More recently, Jeremy has focused on the evolving BEPS landscape and tax developments in Australia, particularly in transfer pricing as it applies to permanent establishments, intellectual property, cross border financing, economic substance and evolving views on value creation, helping Australian clients manage the introduction of the Country-by-Country rules, the new Multinational Anti-Avoidance Law and proposed Diverted Profits Tax.